LNZ100 and LNZ101 Phase 3 Timing
LENZ Therapeutics provided Phase 3 timing and formulation guidance for LNZ100 and LNZ101. LNZ100 is a 1.75% Aceclidine based eye drop while LNZ101 is a 1.75% Aceclidine based eye drop with Brimonidine. Both use LENZ's proprietary preservative free vehicle matrix to maximize comfort, efficacy and bioavailability.

LENZ Therapeutics Provides Phase 3 Timing Guidance

LENZ Therapeutics provided Phase 3 timing and formulation guidance at the Academy and Eyecelerator meetings in November.

LENZ shared they expect to start their pivotal Phase 3 trial in 2Q 2022.  This trial will include 2 eye drop formulations for presbyopia.

LNZ100
1.75% Aceclidine

  • Optimal concentration for a pinhole effect
  • Minimal concern of induced myopia

LNZ101
1.75% Aceclidine + Brimonidine

  • Potential for increased duration
  • Added benefit of eye whitening

Both formulations use LENZ’s proprietary, preservative free vehicle matrix to maximize comfort, efficacy and bioavailability.